סטרפטז 750000 IU ישראל - עברית - Ministry of Health

סטרפטז 750000 iu

genmedix , israel - streptokinase - אבקה להכנת תמיסה לאינפוזיה - streptokinase 750000 iu/vial - streptokinase - streptokinase - acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute or subacute thrombosis of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein.

סטרפטז 1500000 ישראל - עברית - Ministry of Health

סטרפטז 1500000

genmedix , israel - streptokinase - אבקה להכנת תמיסה לזריקה - streptokinase 1500000 iu - streptokinase - streptokinase - systemic administration: in deep vein thromboses, lung embolism, acute myocardial infarction for re-opening of coronary vessels. in acute and subacute thromboses of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein. local administration: in acute myocardial infarction for re-opening of coronary vessels, in acute, subacute and chronic thromboses as well as embolisms of peripheral arteries.

יורוקינאז מדאק 10000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 10000 iu

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 10000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

יורוקינאז מדאק 50000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 50000 iu

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 50000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

יורוקינאז מדאק 100000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 100000 iu

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 100,000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

יורוקינאז מדאק 250000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 250000 iu

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 250000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

יורוקינאז מדאק 500000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 500000 iu

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 500000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

יורוקינאז מדאק 1,000,000 IU ישראל - עברית - Ministry of Health

יורוקינאז מדאק 1,000,000 iu

tzamal bio-pharma ltd - urokinase 1000000 iu - powder for solution for injection - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.